Sun Pharmaceutical Industries Ltd

Large Cap

Healthcare Sector

reflects a positive outlook for the share price

reflects a neutral outlook for the share price

reflects a negative outlook for the share price

The analysts information is for reference only and does not\n  represents an investment recommendation.

Analyst recommendation reflect the views of analysts who follow and write research reports.

Abzorb

Pepfiz

Revital

Volini

Company Information is an introduction to the company’s business that details what it sell, how it was founded, what their mission is, how they manufacture or source their products, and why they serve customers.

Jefferies has reiterated its 'Buy' rating on Sun Pharmaceutical Industries Ltd, setting a target price of Rs 2,100, indicating confidence in the company's growth potential.

Jefferies Maintains Buy Rating on Sun Pharma - 22 Jan, 2026

Sun Pharmaceutical is exploring a $10 billion acquisition of Organon, which would be a transformative move for its US market presence and the largest cross-border deal in Indian pharma.

Sun Pharma Considers Major Acquisition of Organon - 19 Jan, 2026

Sun Pharmaceutical Industries approved warrants to raise funds, while launching Unloxcyt for advanced skin cancer treatment in the US, despite a drop in stock price.

Sun Pharma Launches Skin Cancer Drug and Raises Funds - 16 Jan, 2026

LIC has increased its stake in Sun Pharmaceutical Industries to 5.04% by acquiring shares from the open market. Despite this, Sun Pharma shares fell by 1.7%. The company's specialty business revenue rose 17.1% year-on-year, indicating growth in key areas.

LIC Increases Stake in Sun Pharma to 5.04% - 14 Jan, 2026

Sun Pharma Advanced Research announced a significant 40% workforce reduction, primarily affecting US staff, to optimize costs and enhance future growth. Meanwhile, Morgan Stanley maintains an Overweight rating, citing the company's strategic focus on its specialty portfolio.

Sun Pharma Plans Major Workforce Reduction - 08 Jan, 2026

Sun Pharmaceutical Industries Ltd announces the launch of ILUMYA Pen for plaque psoriasis in Canada. The stock also sees a slight rise, marking five consecutive gains.

Sun Pharma Gains with New ILUMYA Pen Launch - 07 Jan, 2026

Sun Pharmaceutical Industries aims for mid-to-high single digit growth in FY26 while facing potential EPS impacts from US Medicare pricing changes and recalling antifungal products.

Sun Pharma Faces Challenges Amid Growth Targets - 26 Dec, 2025

Price to Earnings Ratio or Price to Earnings Multiple is the ratio of the share price of a stock to its earnings per share (EPS). It provides an indication of whether a stock at its current market price is expensive or cheap.

The price/earnings-to-growth ratio, or the PEG ratio, is a metric that helps investors value a stock by taking into account a company's market price, its earnings, and its future growth prospects.

Enterprise value (EV) is the total value of a company, defined in terms of its financing. It includes both the current share price (market capitalization) and the cost to pay off debt (net debt, or debt minus cash).

Alpha measures the amount that the investment has returned in comparison to the market index or other broad benchmark that it is compared against.

Beta measures a stock's volatility, the degree to which its price fluctuates in relation to the overall stock market. In other words, it gives a sense of the stock's risk compared to that of the greater market.

Dividend yield measures the quantum of earnings by way of total dividends that investors make by investing in that company.

The debt-to-total-assets ratio shows how much of a business is owned by creditors (people it has borrowed money from) compared with how much of the company's assets are owned by shareholders.

Operating cash flow (OCF) is a measure of the amount of cash generated by a company's normal business operations. Operating cash flow indicates whether a company can generate sufficient positive cash flow to maintain and grow its operations.

This widget shows the information about the stock's peers in consideration along with the different data for those peers so that the user can compare the stock with the other similar stock and invest accordingly.

Promoter holding is the amount of share of the company that is owned by the promoters. The promoters are the company's founders, who hold a majority stake in the company's capital.

A foreign institutional investor (FII) is an investor or investment fund investing in a country outside of the one in which it is registered or headquartered.

A mutual fund is a pool of money managed by a professional Fund Manager. It is a trust that collects money from a number of investors who share a common investment objective and invests the same in equities, bonds, money market instruments, and other securities.

Retail investors execute their trades through traditional or online brokerage firms or other types of investment accounts. Retail investors purchase securities for their own personal accounts and often trade in dramatically smaller amounts as compared to institutional investors.

This widget shows the bifurcation of stocks based on the percentage of stake with the different types of shareholders.

This widget will help value the stock based on the Price to Earning ratio of the stock and compare the valuation with the industry value and other similar stocks. It even shows the timeline of the valuation of the stock and its highest and lowest valuation over time.
A Time Series data is provided which compares the historical stock PE with Industry PE over the period of 5 years.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

Netprofit is up for the last 3 quarters, 2.14K Cr → 3.11K Cr (in ₹), with an average increase of 16.3% per quarter

This section gives you an insight into how the profit for the company has been for the last few quarters.

Profit Spike

Revenue is up for the last 3 quarters, 13.57K Cr → 14.94K Cr (in ₹), with an average increase of 4.7% per quarter

This section gives you an insight into how the revenue of the company has moved for the last few quarters.

Revenue Rich

Promoters holdings remained unchanged at 54.48% of holdings in Dec 2025 quarter

This section gives you an insight into how the Promoter Holding has changed for the stock over the last few quarters.

Promoter Holding Unchanged

In the last 3 years, Torrent Pharmaceuticals Ltd has given 148.9% return, outperforming this stock by 95.1%

This section gives you an insight into how the peers have performed as compared to this company in the last 3 years.

Against Peers

In the last 1 year, Torrent Pharmaceuticals Ltd has given 26.0% return, outperforming this stock by 34.5%

This section gives you an insight into how the peers have performed as compared to this company in the last 1 year.

Foreign Institutions have decreased holdings from 16.55% to 16.12% in Dec 2025 quarter

This section gives you an insight into how the FII Holding has changed for the stock over last few quarters.

FII Holding Down

In the last 3 months, SUNPHARMA stock has moved down by -4.5%

This section gives you an insight into the price movement of the stock for the last few quarters.

Price Dip

Mutual Funds have decreased holdings from 12.41% to 12.09% in Dec 2025 quarter

This section gives you an insight into how the Mutual Funds Holding has changed for the stock over last few quarters.

MF Holding Down

Retail Investor have decreased holdings from 8.73% to 8.58% in Dec 2025 quarter

This section gives you an insight into how the Retail Investors Holding has changed for the stock over last few quarters.

Retail Holding Down

S&P BSE 100 ESG

S&P BSE Largecap

S&P BSE 250 LargeMidCap

BSE 200

BSE 500

BSE MFG

BSE Healthcare

Nifty LargeMidcap 250

Nifty100 Eq Weig

S&P BSE 100 LargeCap TMC

S&P BSE Dividend Stability

NIFTY 50

BSE 100

SENSEX

NIFTY 100

S&P BSE SENSEX 50

Nifty Healthcare

Nifty 200

NIFTY PHARMA

S&P BSE Low Volatility

Nifty100 Low Volatility 30

Nifty 500

ICICI Prudential Value Fund Direct Plan Growth

ICICI Prudential Equity & Debt Fund Direct Plan Growth

ICICI Prudential Large Cap Fund Direct Plan Growth

ICICI Prudential India Opportunities Fund Direct Growth

HDFC Balanced Advantage Fund Direct Plan Growth Option

Sun Pharmaceutical Industries Ltd’s net profit jumped 2.56% since last year same period to ₹3,117.95Cr in the Q2 2025-2026. On a quarterly growth basis, Sun Pharmaceutical Industries Ltd has generated 36.83% jump in its net profits since last 3-months.

Sun Pharmaceutical Industries Ltd Earnings Results

In the quarter ending March 2025, Sun Pharmaceutical Industries Ltd has declared dividend of ₹5.50 per share on 22 May 2025 - translating a dividend yield of 1.30%.

Name	Value	Action
MACD level (12,26)	0.05	Bullish
CCI (20)	482.49	Bearish
RSI (14)	57.27	Neutral
Momentum (10)	2.3	Bullish
ADI (14)	26.68	Bullish
Ultimate Oscillator (7,14,28)	31.9	Neutral

Name	Value	Action
SMA (20)	1612.78	Bullish
EMA (20)	1613.22	Bullish
VWMA (20)	1613.11	Bullish
SMA (50)	1613.41	Bullish
EMA (50)	1613.53	Bullish
SMA (200)	1615.78	Bearish
EMA (200)	1615.87	Bearish
KAMA (200)	1613.76	Bullish
DEMA (200)	1612.23	Bullish

Sun Pharmaceutical Industries Ltd (SUNPHARMA)

Summary

Overall

Oscillators

Moving Averages